Published in Vaccine Weekly, August 9th, 2006
Scientists writing in the journal Clinical Cancer Research report, "We have shown previously that the MHC class II-negative murineTS/A adenocarcinoma is rejected in vivo if induced to express MHC class II molecules by transfection of the MHC class II transactivator CIITA. In this study, we explored the immunologic basis of tumor rejection and the correlation between histopathology of tumor tissue and immune rejection."
"Stable TS/A-CIITA transfectants were generated and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly